eyeforpharma Philadelphia 2017: Be the trusted healthcare partner #efpPhilly

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it.

One eyeforpharma Philadelphia. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond.

The 6 sessions will focus on:

  • Commercial Leadership
    The rules of the game have changed: we have moved away from a volume approach. We must recognize that our medicine is not the asset, it is merely one of our assets - another key asset being the understanding we have of our patient's lives. Our metrics have already moved away from sales, towards engagement. Find out how pharma's c-suite are embracing the new customer engagement paradigm.
  • The Heart of Customer Experience
    Make no mistake, it's 2017 and your customers are in charge. A positive, reliable experience at any touch point will be necessary to unleash new levels of engagement, loyalty and the rewards this brings for patients as well as your business. Help your customers succeed as a partner and differentiate your company through the way you engage.
  • Commercial Model Innovation
    Your face-to-face push model has evolved in the face of healthcare consumerization and provider consolidation. It's more vital than ever to develop an effective and sustainable commercial model. Understand the market dynamics and position your teams for industry leadership.
  • Digital Transformation & Technology
    As consumers, digital is key to everything we do. To ensure that your company is leveraging the technology transformation, you must ensure that digital is integral to your business plan. Join leaders in tech and industry and develop a strategic vision to embed digital throughout the organization.
  • Pharma's 'Triple Aim': Access, affordability and adherence
    New strategies are needed to help patients manage healthcare payment concerns and adherence through better assistance and engagement services than ever before. Hear action-driven case studies about the power of empathy in guiding successful patient support.
  • Patients as partners: Co-creation and shared decision-making
    Moving from 'words to action' has been a key imperative for those who want to lead patient-centric change in our industry. Looking at both partnerships with stakeholders and initiatives from within, our sessions will help you achieve 'quick-wins' as well as big transformations. See the full agenda here.

Why you can't miss The eyeforpharma Philadelphia Summit 2017

With 15 years of experience, eyeforpharma has tailored this summit to go beyond the offerings of a normal conference. The 2017 Summit will guarantee:
  • More Than 50 Executive-level Thought Leaders sharing their experience and knowledge. Take this opportunity to transform your organisation, become truly customer-centric and improve healthcare outcomes.
  • NO Sales Pitch: this is an independently researched event committed to equipping you with the techniques and expertise to drive your business. You will take-away actionable insights proven to drive your commercial strategy.
  • 10+ Hours of Dedicated Networking: Identify new business opportunities and develop valuable and lasting relationships with senior-level executives that create partnerships and collaborations beyond what's possible in the office.
  • NEW for 2017 - Innovative Sessions that Deepen Your Thinking: From Think Tanks, to Panel Debates, to Roundtables to Fire-side Chats, we can guarantee you a variety of sessions that will help you identify the answers to common challenges commercial professionals are faced with.
  • Included in your Philly pass: eyeforpharma Philadelphia has just gotten bigger, one-pass will not gain you access to eyeforpharma's "Brand New" Medical Affairs meeting

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

For further information, please visit:
http://www.eyeforpharma.com/philadelphia/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Novartis drug Zykadia receives FDA Priority Review…

Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority R...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Drugs similar to aspirin, ibuprofen could help tre…

A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medici...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

Another record year for Bayer - good progress with…

Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]